Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome.
The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Anavex Life Sciences is at a crucial stage of growth, with a focus on developing upstream compensatory small molecule therapeutic interventions for central nervous system (CNS) conditions. The company's dedication to creating innovative solutions for neurodegenerative and neurodevelopmental disorders demonstrates a commitment to addressing critical medical needs across all age groups.
Anavex Life Sciences has achieved significant milestones in its history, including the development of Blarcamesine (ANAVEX®2-73), a potential therapeutic solution for Alzheimer's disease. Data presented at the CTAD Conference 2024 showed pre-specified efficacy in a Phase IIb/III trial, highlighting the drug's promising impact on countering neurodegeneration and improving autophagy. Additionally, encouraging preliminary biomarker results from an ongoing Phase 2 study of ANAVEX®3-71 for the treatment of schizophrenia demonstrate the company's broadening scope of therapeutic candidates.
Anavex Life Sciences' case studies revolve around the development and efficacy of Blarcamesine (ANAVEX®2-73) in combating Alzheimer's disease. The drug's ability to activate SIGMAR1 and enhance autophagy, thereby countering neurodegeneration and improving immune system functions, demonstrates its potential in addressing critical medical needs. Additionally, ongoing Phase 2 studies of ANAVEX®3-71 for schizophrenia treatment underscore the company's commitment to expanding its therapeutic portfolio and addressing a diverse range of CNS conditions.
Anavex Life Sciences has recently achieved key milestones, including the pre-specified efficacy of Blarcamesine in the Phase IIb/III Alzheimer's trial presented at the CTAD Conference 2024. The company also announced encouraging preliminary biomarker results for ANAVEX®3-71 in the treatment of schizophrenia, highlighting its dedication to developing innovative therapeutic solutions. Anavex Life Sciences' upcoming participation in the H.C. Wainwright 26th Annual Global Investment Conference 2024 underscores its commitment to advancing research and expanding its presence in the healthcare industry.
-
Active
Health Care/Life Sciences
630 5th Avenue 20th floor New York New York 10111 United States...
United States
40
Peter Donhauser (Independent Director)
Christopher U. Missling (President, CEO, Secretary & Director)
Sandra Boenisch (Principal Financial Officer & Treasurer)
Walter E. Kaufmann (Chief Scientific Officer)
-
$6.61
Achieving business success in today’s competitive landscape requires specialized expertise, seamless operations, and continuous innovation. Establishing a Virtual Delivery Center (VDC) can transform your company’s growth journey by ensuring efficiency, scalability, and long-term value.
Why Choose a VDC for Your Company?
1. Cost Optimization:
Save up to 70% on operational costs by leveraging remote teams and streamlined processes.
2. Expert Access:
Gain instant access to highly skilled professionals, ensuring faster and smoother project execution.
3. Scalable Teams:
Scale your team as business needs evolve, from initial project setup to long-term support.
4. Accelerated Timelines:
Leverage 24/7 global teams to reduce project delays and speed up implementation.
5. Continuous Support:
Ensure uninterrupted business performance with ongoing maintenance and updates.
Unlock Business Success with a VDC By establishing a VDC, your company can overcome operational challenges, achieve seamless system integration, and maximize ROI. Stay ahead in today’s dynamic market with a future-ready business strategy powered by a Virtual Delivery Center. Learn More About Us
Book A Meeting To Setup Your VDCAiDOOS Information Wiki provides comprehensive information about products, companies, and individuals.
-
Health Care/Life Sciences
630 5th Avenue 20th floor New York New York 10111 United States...
United States
40+
-
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome.
The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Achieving business success in today’s competitive landscape requires specialized expertise, seamless operations, and continuous innovation. Establishing a Virtual Delivery Center (VDC) can transform your company’s growth journey by ensuring efficiency, scalability, and long-term value.
Why Choose a VDC for Your Company?
1. Cost Optimization:
Save up to 70% on operational costs by leveraging remote teams and streamlined processes.
2. Expert Access:
Gain instant access to highly skilled professionals, ensuring faster and smoother project execution.
3. Scalable Teams:
Scale your team as business needs evolve, from initial project setup to long-term support.
4. Accelerated Timelines:
Leverage 24/7 global teams to reduce project delays and speed up implementation.
5. Continuous Support:
Ensure uninterrupted business performance with ongoing maintenance and updates.
Unlock Business Success with a VDC By establishing a VDC, your company can overcome operational challenges, achieve seamless system integration, and maximize ROI. Stay ahead in today’s dynamic market with a future-ready business strategy powered by a Virtual Delivery Center. Learn More About Us
Book A Meeting To Setup Your VDC